Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial

1

Gastric cancer has a high incidence and mortality rate, with surgery being the primary treatment despite recurrence risks.
2

The Intergroup-0116 study showed that concurrent chemoradiation therapy significantly improves overall and relapse-free survival after surgery.
3

Adjuvant chemotherapy after D2 gastrectomy has been shown to improve survival rates compared to surgery alone in several clinical trials.
4

The ARTIST 2 trial indicated no significant difference in efficacy between chemotherapy alone and concurrent chemoradiation after D2 gastrectomy.
5

This study aims to assess the impact of adding radiotherapy to the SOX chemotherapy regimen on disease-free survival after D2 gastrectomy.

Jama Network Open

by Xin Wang, Ouying Yan, Jitao Zhou, Feng Wen, Yali Shen, Zhiping Li, Qiu Li, Wenling Wang, Xiaohong Cai, Shisheng Tan, Zi Wang, Qing Qiao, Dan Cao, Meng Qiu, Jiyan Liu, Hongfeng Gou, Ming Liu, Cheng Yi, Yu Yang, Qing Zhu, Deyun Luo, Yaqin Zhao, Ye Chen, Shang Wang, Qiaoli Wang, Ke Cheng, Min Ren, Xin Liu, Feng Xu, Feng Bi
June 15, 2026

1